Cerebrospinal fluid exploratory proteomics and ketamine metabolite pharmacokinetics in human volunteers after ketamine infusion-Reference-Cited by-同舟云学术

Cerebrospinal fluid exploratory proteomics and ketamine metabolite pharmacokinetics in human volunteers after ketamine infusion

Published:2023-12 Issue:12 Volume:26 Page:108527
ISSN:2589-0042
Container-title:iScience
language:en
Short-container-title:iScience

Author:

Moaddel Ruin^ORCID,Farmer Cristan A.,Yavi Mani,Kadriu Bashkim,Zhu Min,Fan Jinshui,Chen Qinghua,Lehrmann Elin,Fantoni Giovanna,De Supriyo,Mazucanti Caio H.,Acevedo-Diaz Elia E.,Yuan Peixiong,Gould Todd D.,Park Lawrence T.,Egan Josephine M.,Ferrucci Luigi,Zarate Carlos A.

Funder

National Institutes of Health

National Institute of Mental Health

National Institute on Aging

Publisher

Elsevier BV

Subject

Multidisciplinary

Reference119 articles.

1. Antidepressant effects of ketamine in depressed patients;Berman;Biol. Psychiatry,2000

2. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression;Diazgranados;Arch. Gen. Psychiatry,2010

3. Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial;Zarate;Biol. Psychiatry,2012

4. Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD);Fava;Mol. Psychiatry,2020

5. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial;Murrough;Am. J. Psychiatry,2013

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Phase 1 Assessment of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of (2R,6R)‐Hydroxynorketamine in Healthy Volunteers;Clinical Pharmacology & Therapeutics;2024-07-25